Cited by 558Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

Open access

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group·2010·The Lancet

DOI 10.1016/s0140-6736(10)60310-8PMC PMC2988223

Open this paper in CoChat — free account Open PDF

Abstract

Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely produces extra benefits is uncertain. We aimed to establish efficacy and safety of more intensive statin treatment in patients at high cardiovascular risk.Methods We undertook a double-blind randomised trial in 12,064 men and women aged 18-80 years with a history of myocardial infarction. Participants were either currently on or had clear indication for statin therapy, and had a total cholesterol concentration of at least 3·5 mmol/L if already on a statin or 4·5 mmol/L if not. Randomisation to either 80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm. Participants were assessed at 2, 4, 8, and 12 months after randomisation and then every 6 months until final follow-up. The primary endpoint was major vascular events, defined as coronary death, myocardial infarction, stroke, or arterial revascularisation. Analysis was by intention to treat. This study is registered, number ISRCTN74348595.Findings 6031 participants were allocated 80 mg simvastatin daily, and 6033 allocated 20 mg simvastatin daily. During a mean follow-up of 6·7 (SD 1·5) years, allocation to 80 mg simvastatin produced an average 0·35 (SE 0·01) mmol/L greater reduction in LDL cholesterol compared with allocation to 20 mg. Major vascular events occurred in 1477 (24·5%) participants allocated 80 mg simvastatin versus 1553 (25·7%) of those allocated 20 mg, corresponding to a 6% proportional reduction (risk ratio 0·94, 95% CI 0·88-1·01; p=0·10). There were no apparent differences in numbers of haemorrhagic strokes (24 [0·4%] vs 25 [0·4%]) or deaths attributed to vascular (565 [9·4%] vs 572 [9·5%]) or non-vascular (399 [6·6%] vs 398 [6·6%]) causes. Compared with two (0·03%) cases of myopathy in patients taking 20 mg simvastatin daily, there were 53 (0·9%) cases in the 80 mg group.Interpretation The 6% (SE 3·5%) reduction in major vascular events with a further 0·35 mmol/L reduction in LDL cholesterol in our trial is consistent with previous trials. Myopathy was increased with 80 mg simvastatin daily, but intensive lowering of LDL cholesterol can be achieved safely with other regimens.Funding Merck; The Clinical Trial Service Unit also receives funding from the UK Medical Research Council and the British Heart Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)60310-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638

Show all 38 references

Sorted by citations

Items 101–200 of 557

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial
Hong, S. J., Jeong, H. S., Ahn, J. C., Cha, D., Won, K. H., Kim, W., Cho, S. K., Kim, S. Y., Yoo, B., Sung, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.12.018 · Cited by 65
An overview of statin-induced myopathy and perspectives for the future
Nikolić, D., Banach, M., Chianetta, R., Luzzu, L. M., Stoian, A. P., Diaconu, C. C., Citarrella, R., Montalto, G., & Rizzo, M. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1747431 · Cited by 65
Use of Administrative Data to Estimate the Incidence of Statin-Related Rhabdomyolysis
Heckbert, S. R. (2012) · JAMA · doi:10.1001/jama.2012.489 · Cited by 61
Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling
Perera, R., McFadden, E. C., McLellan, J., Lung, T. W.-C., Clarke, P., Pérez, T., Fanshawe, T. R., Dalton, A., Farmer, A. A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 63
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Colhoun, H. M., Robinson, J. G., Farnier, M., Cariou, B., Blom, D. J., Kereiakes, D. J., Lorenzato, C., Pordy, R. C., & Chaudhari, U. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-121 · Cited by 61
“However, high-intensity statin therapy may be insufficient to achieve LDL-C targets when utilizing a ‘treat-to–target’ approach, may not be tolerated, or may be associated with a higher risk of myopathy [7].”
Background
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
Lee, Y., Hong, S., Kang, W. C., Hong, B., Lee, J., Lee, J., Cho, H.-J., Yoon, J., Lee, S., Ahn, C., et al. (2023) · BMJ · doi:10.1136/bmj-2023-075837 · Cited by 68
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts
Teixeira, L., Temerozo, J. R., Pereira-Dutra, F. S., Ferreira, A. C., Mattos, M., Gonçalves, B. S., Sacramento, C. Q., Palhinha, L., Cunha‐Fernandes, T., Dias, S. D. S. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.820131 · Cited by 55
Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
VersorgungsLeitlinie, N. (2011) · Cited by 58
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
Azemawah, V., Movahed, M. R., Centuori, P., Penaflor, R., Riel, P. L., Situ, S., Shadmehr, M., & Hashemzadeh, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06904-x · Cited by 58
Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease
Virani, S. S., Woodard, L., Chitwood, S. S., Landrum, C. R., Urech, T. H., Wang, D., Murawsky, J., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.013 · Cited by 56
Meta-analysis of statins in chronic kidney disease: who benefits?
Messow, C., & Isles, C. (2017) · QJM · doi:10.1093/qjmed/hcx040 · Cited by 54
Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis
de Vries, F. M., Kolthof, J., Postma, M. J., Denig, P., & Hak, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111247 · Cited by 56
“1): the 4S [25], the ASPEN [7], the CARE [26], the HPS [27] and the LIPID [28] trial for the comparison of a standard-dose statin with placebo and the A to Z [13], the PROVE-IT TIMI [14], the SEARCH [15] and the TNT [16] trials for the comparison of standard-dose statin treatment with intensive-dose statin treatment (…”
BackgroundMethodInfluential
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 54
Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/563717 · Cited by 53
Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis
Li, X., Qi, H., Cui, W., Wang, Z., Fu, X., Li, T., Ma, H., Yang, Y., & Yu, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.018 · Cited by 52
Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis
Pinyopornpanish, K., Al-Yaman, W. A., Butler, R. S., Carey, W. W., McCullough, A. J., & Romero‐Marrero, C. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001347 · Cited by 51
Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials
Rahimi, K., Majoni, W., Merhi, A., & Emberson, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs005 · Cited by 50
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
Bandyopadhyay, D., Qureshi, A., Ghosh, S., Ashish, K., Heise, L. R., Hajra, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/8598054 · Cited by 55
“However, myopathy cases were reported in a higher number, among 80mg simvastatin users [29].”
Background
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
Vonbank, A., Drexel, H., Agewall, S., Lewis, B. S., Dopheide, J. F., Kjeldsen, K. P., Ceconi, C., Savarese, G., Rosano, G. M. C., Waßmann, S., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy028 · Cited by 50
Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis
Judge, C. S., Ruttledge, S., Costello, M. M., Murphy, R., Loughlin, E. A., Alvarez‐Iglesias, A., Ferguson, J. P., Gorey, S., Nolan, A. M., Canavan, M. D., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.02.018 · Cited by 49
Physical Activity, Sedentary Leisure Time, Circulating Metabolic Markers, and Risk of Major Vascular Diseases
Pang, Y., Kartsonaki, C., Du, H., Millwood, I. Y., Guo, Y., Chen, Y., Bian, Z., Yang, L., Walters, R. G., Bragg, F., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002527 · Cited by 50
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering
Sniderman, A. D., Thanassoulis, G., Couture, P., Williams, K., Alam, A., & Furberg, C. D. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.05.004 · Cited by 49
Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative
Desai, P. M., Chlebowski, R. T., Cauley, J. A., Manson, J. E., Wu, C., Martin, L. W., Jay, A. M., Bock, C. H., Coté, M. L., Petrucelli, N., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0562 · Cited by 49
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
Ballantyne, C. M., Hoogeveen, R. C., Raya, J. L., Cain, V. A., Palmer, M. K., & Karlson, B. W. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.10.022 · Cited by 49
Chronic kidney disease in acute coronary syndromes
Marenzi, G. (2012) · World Journal of Nephrology · doi:10.5527/wjn.v1.i5.134 · Cited by 48
A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin
Ran, D., Nie, H.-J., Gao, Y.-L., Deng, S., Du, J., Liu, Y., Jing, X., & She, Q. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.099 · Cited by 48
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Griffin, S. J., Bethel, M. A., Holman, R. R., Khunti, K., Wareham, N. J., Brierley, G., Davies, M. J., Dymond, A., Eichenberger, R., Evans, P. H., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22180 · Cited by 50
Clinical Pharmacology of Statins: an Update
Ferri, N., & Corsini, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00844-w · Cited by 52
Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45
“Moreover, the number of statin-intolerant patients is rising, which is manifested by the use of higher statin doses to achieve more stringent LDL-C targets [1, 29].”
Background
Prognosis of vulnerable plaque on computed tomographic coronary angiography with normal myocardial perfusion image
Otsuka, K., Fukuda, S., Tanaka, A., Nakanishi, K., Taguchi, H., Yoshiyama, M., Shimada, K., & Yoshikawa, J. (2013) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet232 · Cited by 47
“9% per year).(27,28) These findings could justify the assessment of vulnerable plaques without abnormalities using myocardial perfusion for predicting future ACS events.”
Background
Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
Anyanwagu, U., IDRIS, I. R., & Donnelly, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.274 · Cited by 49
Statins and myocardial remodelling: cell and molecular pathways
Porter, K. E., & Turner, N. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001931 · Cited by 46
Lipid Testing and Statin Dosing After Acute Myocardial Infarction
Wang, W. T., Hellkamp, A. S., Doll, J. A., Thomas, L. E., Návar, A. M., Fonarow, G. C., Julien, H. M., Peterson, E. D., & Wang, T. Y. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006460 · Cited by 47
Acyltransferase inhibitors: a patent review (2010–present)
Ohshiro, T., & Tomoda, H. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.989833 · Cited by 45
“However, clinical data have revealed several problems with their use: i) they only reduce the risk of complications and related death from CV events by 30% [7]; ii) they cause the serious adverse side effect of muscle injury (myopathy and rhabdomyolysis) [8,9]; and iii) they show none or low efficacy against homozygou…”
Background
The Impact of Pharmacogenomics in Personalized Medicine
Singh, D. B. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_110 · Cited by 50
Statins and muscle pain
Pergolizzi, J. V., Coluzzi, F., Colucci, R. D., Olsson, H., LeQuang, J. A., Al‐Saadi, J., & Magnusson, P. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1734451 · Cited by 47
“doses and this finding must be viewed as incidental [78].”
Background
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
Hopewell, J. C., Offer, A. R., Haynes, R., Bowman, L. J., Li, J., Chen, F., Bulbulia, R. A., Lathrop, M. G., Baigent, C., Landray, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa574 · Cited by 45
A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 45
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
Șerban, M.-C., Banach, M., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 43
“statin-moderate users [49,50] or a deterioration of glucose control in patients on intensive statin therapy.”
Background
Lipid‐Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 48
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
Reith, C. A., Blackwell, L. S., Emberson, J., Preiss, D., Spata, E., Davies, K., Halls, H. J., Harper, C., Holland, L., Wilson, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01578-8 · Cited by 51
A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans
Andreux, P. A., Mouchiroud, L., Wang, X., Jovaisaite, V., Mottis, A., Bichet, S., Moullan, N., Houtkooper, R. H., & Auwerx, J. H. (2014) · Scientific Reports · doi:10.1038/srep05285 · Cited by 45
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease
Dorresteijn, J. A. N., Boekholdt, S. M., van der Graaf, Y., Kastelein, J. J. P., LaRosa, J. C., Pedersen, T. R., DeMicco, D. A., Ridker, P. M., Cook, N. R., & Visseren, F. L. J. (2013) · Circulation · doi:10.1161/circulationaha.112.000712 · Cited by 43
“but it is often argued that this problem could be specific to simvastatin.(3) Moreover, higher rates of myalgia, diarrhea, abdomi-”
Background
Low Vitamin D as a Risk Factor for the Development of Myalgia in Patients Taking High-Dose Simvastatin: A Retrospective Review
Mergenhagen, K. A., Ott, M., Heckman, K., Rubin, L. M., & Kellick, K. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.02.023 · Cited by 43
“Rhabdomyolysis was diagnosed in 7 patients in the 80-mg group and no patients in the 20-mg group.(3) In this retrospective study, incidence of myalgia, myopathy, and rhabdomyolysis was analyzed in a veteran population prescribed simvastatin 80 mg.”
BackgroundMethodInfluential
Statin tolerability: In defence of placebo-controlled trials
Tobert, J. A., & Newman, C. B. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315602861 · Cited by 43
Isoform-Specific Inhibitors of Acats: Recent Advances and Promising Developments
Ohshiro, T., & Tomoda, H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.158 · Cited by 42
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Davis, J. W., & Weller, S. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043714 · Cited by 46
Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
LaRosa, J. C., Pedersen, T. R., Somaratne, R. M., & Wasserman, S. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.052 · Cited by 43
Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors
Teli, M. K., & Rajanikant, G. K. (2012) · Organic and Medicinal Chemistry Letters · doi:10.1186/2191-2858-2-25 · Cited by 41
A Double‐Blind , Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease
Lin, C., Chang, C., Tai, C., Cheng, M., Chen, Y., Chao, Y., Huang, T., Yen, R., & Wu, R. (2021) · Movement Disorders · doi:10.1002/mds.28474 · Cited by 40
Amiodarone Therapy: Updated Practical Insights
Șorodoc, V., Indrei, L., Dobroghii, C., Asaftei, A., Ceasovschih, A., Constantin, M., Lionte, C., Morărașu, B. C., Diaconu, A.-D., & Șorodoc, L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206094 · Cited by 38
Co‐administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population
Bakhai, A., Rigney, U., Hollis, S., & Emmas, C. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2308 · Cited by 38
Osteogenic/Odontogenic Bioengineering with co-Administration of Simvastatin and Hydroxyapatite on Poly Caprolactone Based Nanofibrous Scaffold
Samiei, M., Aghazadeh, M., Alizadeh, E., Aminabadi, N. A., Davaran, S., Shirazi, S., Ashrafi, F., & Salehi, R. (2016) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2016.047 · Cited by 38
Lipid‐Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta‐Analysis of Exclusion Criteria
Aeschbacher‐Germann, M., Kaiser, N., Speierer, A., Blum, M. R., Bauer, D. C., Giovane, C. D., Aujesky, D., Gencer, B., Rodondi, N., & Moutzouri, E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026551 · Cited by 41
Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial
John, M., Cockcroft, J., McKeever, T. M., Coward, W. R., Shale, D. J., Johnson, S. R., Thornton, J., Harrison, T. W., Knox, A. J., & Bolton, C. E. (2015) · International Journal of COPD · doi:10.2147/copd.s76061 · Cited by 37
Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature
Colbert, J. D., & Stone, J. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.021 · Cited by 37
“19) for the development of diabetes.(23) In a small study of hypercholesterolemic patients, Koh et al.”
The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations
Agarwala, A., Kulkarni, S., & Maddox, T. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0995-6 · Cited by 39
Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial
Kumari, M., Martande, S., Pradeep, A. R., & Naik, S. B. (2016) · Journal of Periodontology · doi:10.1902/jop.2016.130227 · Cited by 36
Ezetimibe plus a Statin after Acute Coronary Syndromes
Silbernagel, G., Baumgartner, I., & März, W. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509363 · Cited by 36
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
“7 years for SEARCH) [2,12].”
BackgroundMethodResultInfluential
Analysis of repeated leukocyte DNA methylation assessments reveals persistent epigenetic alterations after an incident myocardial infarction
Ward-Caviness, C. K., Agha, G., Chen, B. H., Pfeiffer, L., Wilson, R., Petra, W., Gieger, C., Schwartz, J. D., Vokonas, P., Hou, L., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0588-7 · Cited by 36
Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients
Ribeiro, R. A., Ziegelmann, P. K., Duncan, B. B., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., Moriguchi, E. H., & Polanczyk, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.128 · Cited by 34
“The only item with larger potential to bias was the allocation to study groups: only twenty studies reported on how it was concealed [16,17,19,22,24,25,27,31,34, 36,43,44,47–49,53,59,60,64,65].”
Background
Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin with HMG-CoA Reductase Inhibitors
Bland, C. M., Bookstaver, P. B., Lu, K., Dunn, B. L., & Rumley, K. F. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02910-14 · Cited by 34
“Higher doses of simvastatin (specifically the 80-mg dose) have been associated with increased rates of musculoskeletal adverse events and rhabdomyolysis compared to lower doses (19, 20).”
Background
[The Cardiovascular Disease Risk Factors Knowledge Level (CARRF-KL) Scale: a validity and reliability study].
Arıkan, İ., Metintaş, S., Kalyoncu, C., & Yıldız, Z. (2009) · PubMed · Cited by 39
Examining the nocebo effect of statins through statin adverse events reported in the food and drug administration adverse event reporting system
Moon, J., Cohen Sedgh, R., & Jackevicius, C. A. (2021) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007480 · Cited by 33
Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 34
Statins and diabetes risk: Fact, fiction, and clinical implications
Rocco, M. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12091 · Cited by 32
Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial
Ueshima, K., Itoh, H., Kanazawa, N., Komuro, I., Nagai, R., Takeuchi, M., Yamazaki, T., & for the EMPATHY study group (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33563 · Cited by 33
Accounting for Clinical Action Reduces Estimates of Gender Disparities in Lipid Management for Diabetic Veterans
Vimalananda, V. G., Miller, D. R., Hofer, T. P., Holleman, R. G., Klamerus, M. L., & Kerr, E. A. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2340-5 · Cited by 34
Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects
Peto, R., & Collins, R. (2018) · Circulation · doi:10.1161/circulationaha.118.036846 · Cited by 33
Approach to Statin Use in 2016: an Update
Miller, P. E., & Martin, S. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0578-1 · Cited by 32
Molecular structures of human ACAT2 disclose mechanism for selective inhibition
Long, T., Liu, Y., & Li, X. (2021) · Structure · doi:10.1016/j.str.2021.07.009 · Cited by 32
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 31
Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database
Lee, J., Noh, Y., Shin, S., Lim, H., Park, R. W., Bae, S. K., Oh, E., Kim, G. J., Kim, J. H., & Lee, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117150 · Cited by 31
Disorders of Lipid Metabolism
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
Fasting for Lipid Testing: Is It Worth the Trouble?
Khera, A. V., & Mora, S. (2012) · Archives of Internal Medicine · doi:10.1001/2013.jamainternmed.263 · Cited by 27
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Goh, M., & Sinn, D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0366 · Cited by 24
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy
Liberale, L., Carbone, F., Camici, G. G., & Montecucco, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111764 · Cited by 31
“Recently, a specific analysis investigated specific population such as elderly people and the benefit of statin treatment in secondary prevention remained valid, although some warnings have been raised for specific high-dose regimens [31,32].”
Background
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients
Tison, F., Nègre‐Pagès, L., Meissner, W. G., Dupouy, S., Li, Q., Thiolat, M.-L., Thiollier, T., Galitzky, M., Ory‐Magne, F., Milhet, A., et al. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.12.003 · Cited by 29
Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients
Castro, M. R., Simon, G., Cha, S. S., Yawn, B. P., Melton, L. J., & Caraballo, P. J. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3583-0 · Cited by 28
Clinical Pharmacogenomics
Adams, S. M., Crisamore, K. R., & Empey, P. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02730218 · Cited by 29
Cocaethylene: When Cocaine and Alcohol Are Taken Together
Pergolizzi, J. V., Breve, F., Magnusson, P., LeQuang, J. A., & Varrassi, G. (2022) · Cureus · doi:10.7759/cureus.22498 · Cited by 31
“Cocaethylene increases heart rate and blood pressure more than cocaine [27].”
Background
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 30
Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement
Cai, A., Li, L., Zhang, Y., Mo, Y., Li, Z., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/472845 · Cited by 29
“Hindawi Publishing Corporation Disease Markers Volume 35 (2013), Issue 6, Pages 857–862 http://dx.doi.org/10.1155/2013/472845”
BackgroundInfluential
Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endothelial Function
Ye, Y., Zhao, X., Zhai, G., Guo, L.-L., Tian, Z., & Zhang, S. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412449384 · Cited by 29
Long-term efficacy of pitavastatin versus simvastatin
Eriksson, M., Budinski, D., & Hounslow, N. J. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0057-6 · Cited by 28
Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose
Spector, R., & Snapinn, S. M. (2011) · Pharmacology · doi:10.1159/000322999 · Cited by 28
Simvastatin interactions with other drugs
Florentin, M., & Elisaf, M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.670633 · Cited by 28
“2% patients in the 80 mg group experienced rhabdomyolysis versus none of the patients taking simvastatin 20 mg [15].”
Background
What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 29
High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients
Yu, S., Jin, J., Chen, Z., & Luo, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01369-6 · Cited by 28
Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults
Yi, S., An, S. J., Park, H., Yi, J., & Ohrr, H. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac029 · Cited by 28
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus
Beard, A., Hofer, T. P., Downs, J. R., Lucatorto, M. A., Klamerus, M. L., Holleman, R. G., & Kerr, E. A. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966697 · Cited by 27
Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
Abbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 28
Differences in Action of Atorvastatin and Ezetimibe in Lowering Low-Density Lipoprotein Cholesterol and Effect on Endothelial Function
Matsue, Y., Matsumura, A., Suzuki, M., Hashimoto, Y., & Yoshida, M. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0033 · Cited by 27
The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis
Zhou, Q., Jiao, Z., Liu, Y., Devreotes, P. N., & Zhang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1234713 · Cited by 26

Authors: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
Corresponding author: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
Venue: The Lancet
Publisher: Elsevier BV
Published: 2010-11
Volume: 376
Issue: 9753
Pages: 1658-1669
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(10)60310-8
PMC: PMC2988223
OpenAlex: W1523152575
Cited by: 558
References: 38
Citations by year: 2026: 6 · 2025: 10 · 2024: 20 · 2023: 23 · 2022: 28 · 2021: 22 · 2020: 29 · 2019: 31 · 2018: 33 · 2017: 35 · 2016: 40 · 2015: 47 · 2014: 52 · 2013: 50 · 2012: 68
FWCI: 61.00
Type: journal article
Language: en
Update notices: erratum (2011-01-08)
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (submittedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: British Heart Foundation (PG/12/32/29544)
University of Southampton
University of Oxford
Medical Research Council (MC_EX_G0801669)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: simvastatin, LDL cholesterol lowering, high-intensity statin therapy, myocardial infarction survivors, major vascular events, coronary artery disease, stroke, cardiovascular mortality, statin safety, lipid-lowering therapy, high cardiovascular risk patients, dose comparison, hemorrhagic stroke, coronary death, myocardial infarction recurrence, secondary prevention
MeSH terms: Adult, Aged, Aged, 80 and over, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Triglycerides, Simvastatin, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks